289 related articles for article (PubMed ID: 34845361)
21. A Novel Nrf2 Pathway Inhibitor Sensitizes Keap1-Mutant Lung Cancer Cells to Chemotherapy.
Zhang D; Hou Z; Aldrich KE; Lockwood L; Odom AL; Liby KT
Mol Cancer Ther; 2021 Sep; 20(9):1692-1701. PubMed ID: 34158350
[TBL] [Abstract][Full Text] [Related]
22. Identification of an adaptor protein that facilitates Nrf2-Keap1 complex formation and modulates antioxidant response.
Zhang Y; Hou Y; Liu C; Li Y; Guo W; Wu JL; Xu D; You X; Pan Y; Chen Y
Free Radic Biol Med; 2016 Aug; 97():38-49. PubMed ID: 27212020
[TBL] [Abstract][Full Text] [Related]
23. Directly interact with Keap1 and LPS is involved in the anti-inflammatory mechanisms of (-)-epicatechin-3-gallate in LPS-induced macrophages and endotoxemia.
Chiou YS; Huang Q; Ho CT; Wang YJ; Pan MH
Free Radic Biol Med; 2016 May; 94():1-16. PubMed ID: 26878775
[TBL] [Abstract][Full Text] [Related]
24. A Naturally-Occurring Dominant-Negative Inhibitor of Keap1 Competitively against Its Negative Regulation of Nrf2.
Qiu L; Wang M; Zhu Y; Xiang Y; Zhang Y
Int J Mol Sci; 2018 Jul; 19(8):. PubMed ID: 30042301
[TBL] [Abstract][Full Text] [Related]
25. Effects of deficiency of Kelch-like ECH-associated protein 1 on skeletal organization: a mechanism for diminished nuclear factor of activated T cells cytoplasmic 1 during osteoclastogenesis.
Sakai E; Morita M; Ohuchi M; Kido MA; Fukuma Y; Nishishita K; Okamoto K; Itoh K; Yamamoto M; Tsukuba T
FASEB J; 2017 Sep; 31(9):4011-4022. PubMed ID: 28515152
[TBL] [Abstract][Full Text] [Related]
26. Protection against oxidative stress mediated by the Nrf2/Keap1 axis is impaired in Primary Biliary Cholangitis.
Wasik U; Milkiewicz M; Kempinska-Podhorodecka A; Milkiewicz P
Sci Rep; 2017 Mar; 7():44769. PubMed ID: 28333129
[TBL] [Abstract][Full Text] [Related]
27. Miconazole Contributes to NRF2 Activation by Noncanonical P62-KEAP1 Pathway in Bladder Cancer Cells.
Tsai TF; Chen PC; Lin YC; Chou KY; Chen HE; Ho CY; Lin JF; Hwang TI
Drug Des Devel Ther; 2020; 14():1209-1218. PubMed ID: 32273683
[TBL] [Abstract][Full Text] [Related]
28. Novel NRF2-activated cancer treatments utilizing synthetic lethality.
Baird L; Kensler TW; Yamamoto M
IUBMB Life; 2022 Dec; 74(12):1209-1231. PubMed ID: 36200139
[TBL] [Abstract][Full Text] [Related]
29. Molecular mechanisms for the regulation of Nrf2-mediated cell proliferation in non-small-cell lung cancers.
Yamadori T; Ishii Y; Homma S; Morishima Y; Kurishima K; Itoh K; Yamamoto M; Minami Y; Noguchi M; Hizawa N
Oncogene; 2012 Nov; 31(45):4768-77. PubMed ID: 22249257
[TBL] [Abstract][Full Text] [Related]
30. Thioredoxin reductase-1 levels are associated with NRF2 pathway activation and tumor recurrence in non-small cell lung cancer.
Delgobo M; Gonçalves RM; Delazeri MA; Falchetti M; Zandoná A; Nascimento das Neves R; Almeida K; Fagundes AC; Gelain DP; Fracasso JI; Macêdo GB; Priori L; Bassani N; Bishop AJR; Forcelini CM; Moreira JCF; Zanotto-Filho A
Free Radic Biol Med; 2021 Dec; 177():58-71. PubMed ID: 34673143
[TBL] [Abstract][Full Text] [Related]
31. PM
Li R; Zhao C; Zhang Y; Huang W; Wang J; Cao G; Cai Z
Toxicol Mech Methods; 2024 Jun; 34(5):517-526. PubMed ID: 38293967
[TBL] [Abstract][Full Text] [Related]
32. The discovery and characterization of K-563, a novel inhibitor of the Keap1/Nrf2 pathway produced by Streptomyces sp.
Hori R; Yamaguchi K; Sato H; Watanabe M; Tsutsumi K; Iwamoto S; Abe M; Onodera H; Nakamura S; Nakai R
Cancer Med; 2019 Mar; 8(3):1157-1168. PubMed ID: 30735010
[TBL] [Abstract][Full Text] [Related]
33. LKB1 and KEAP1/NRF2 Pathways Cooperatively Promote Metabolic Reprogramming with Enhanced Glutamine Dependence in
Galan-Cobo A; Sitthideatphaiboon P; Qu X; Poteete A; Pisegna MA; Tong P; Chen PH; Boroughs LK; Rodriguez MLM; Zhang W; Parlati F; Wang J; Gandhi V; Skoulidis F; DeBerardinis RJ; Minna JD; Heymach JV
Cancer Res; 2019 Jul; 79(13):3251-3267. PubMed ID: 31040157
[TBL] [Abstract][Full Text] [Related]
34. Therapeutic targeting of the NRF2 and KEAP1 partnership in chronic diseases.
Cuadrado A; Rojo AI; Wells G; Hayes JD; Cousin SP; Rumsey WL; Attucks OC; Franklin S; Levonen AL; Kensler TW; Dinkova-Kostova AT
Nat Rev Drug Discov; 2019 Apr; 18(4):295-317. PubMed ID: 30610225
[TBL] [Abstract][Full Text] [Related]
35. The KEAP1-NRF2 pathway: Targets for therapy and role in cancer.
Adinolfi S; Patinen T; Jawahar Deen A; Pitkänen S; Härkönen J; Kansanen E; Küblbeck J; Levonen AL
Redox Biol; 2023 Jul; 63():102726. PubMed ID: 37146513
[TBL] [Abstract][Full Text] [Related]
36. Hydrogen Sulfide Alleviates Liver Injury Through the S-Sulfhydrated-Kelch-Like ECH-Associated Protein 1/Nuclear Erythroid 2-Related Factor 2/Low-Density Lipoprotein Receptor-Related Protein 1 Pathway.
Zhao S; Song T; Gu Y; Zhang Y; Cao S; Miao Q; Zhang X; Chen H; Gao Y; Zhang L; Han Y; Wang H; Pu J; Xie L; Ji Y
Hepatology; 2021 Jan; 73(1):282-302. PubMed ID: 32219872
[TBL] [Abstract][Full Text] [Related]
37. Butyrate Drives Metabolic Rewiring and Epigenetic Reprogramming in Human Colon Cancer Cells.
Wang L; Shannar AAF; Wu R; Chou P; Sarwar MS; Kuo HC; Peter RM; Wang Y; Su X; Kong AN
Mol Nutr Food Res; 2022 Jun; 66(12):e2200028. PubMed ID: 35429118
[TBL] [Abstract][Full Text] [Related]
38. Targeting Keap1 by miR-626 protects retinal pigment epithelium cells from oxidative injury by activating Nrf2 signaling.
Xu XZ; Tang Y; Cheng LB; Yao J; Jiang Q; Li KR; Zhen YF
Free Radic Biol Med; 2019 Nov; 143():387-396. PubMed ID: 31446056
[TBL] [Abstract][Full Text] [Related]
39. Association of nanoparticles and Nrf2 with various oxidative stress-mediated diseases.
Thiruvengadam R; Venkidasamy B; Samynathan R; Govindasamy R; Thiruvengadam M; Kim JH
Chem Biol Interact; 2023 Aug; 380():110535. PubMed ID: 37187268
[TBL] [Abstract][Full Text] [Related]
40. Beyond repression of Nrf2: An update on Keap1.
Kopacz A; Kloska D; Forman HJ; Jozkowicz A; Grochot-Przeczek A
Free Radic Biol Med; 2020 Sep; 157():63-74. PubMed ID: 32234331
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
